AirSculpt Technologies, Inc. (AIRS)
NASDAQHealth CareMedical - Care FacilitiesSnapshot 2026-09-09
$2.61-3.69%
Close 2026-09-09 · 1-day change
NASDAQHealth CareMedical - Care FacilitiesSnapshot 2026-09-09
Warn: Management is running behind on a stated commitment.
AirSculpt is growing revenue from $33.44M in 2025-Q4 to $39.39M in 2026-Q1. The company affirms full year 2026 revenue guidance of $151M to $157M. It leads in minimally invasive body contouring with a growing practitioner network. New management hires and stable guidance support a recovery.
The company remains loss-making with negative EPS expected through 2027. Recent sharp share price selloff reflects investor concerns. Revenue growth is slow at about 2% expected next year. Past earnings misses and executive departures raise execution risks.
The market prices in about 2% revenue growth and continued losses. Our fair value near $1.97 reflects a turnaround story but the stock is down 26% from highs. We see risk that the company may not meet its revenue targets or improve profitability soon.
Breaks if: Loss of key executives or leadership turmoil
Breaks if: EPS remains below -$0.03 beyond FY27
Annual revenue falls below $151 million in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround opportunity in the healthcare sector. The company is currently loss-making but has stable management and strong recent performance, despite facing high risks.
The market seems to have priced in a justified valuation, with low fragility and a slight expectations gap. AIRS is currently trading at a premium compared to its peers, indicating that some positive performance is already expected.
Management has reaffirmed revenue guidance for 2026, but recent results show a slight decline in revenue and adjusted EBITDA. With a near-term risk of missing earnings again, the fundamentals may remain under pressure unless management can demonstrate improved execution.
The future performance of AIRS hinges on its ability to meet or exceed guidance in upcoming quarters. Additionally, broader sector performance, particularly from major healthcare players, will influence AIRS's trajectory.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The reaffirmation of full year 2026 revenue guidance supports growth objectives. There are no new threats impacting the thesis.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Reaffirm full year 2026 revenue guidance at approximately $151 to $157 million.
Stated as a priority in 3 of last 3 quarters. Management reaffirmed full year 2026 revenue guidance at approximately $151 to $157 million. Revenue declined slightly from $44.0 million in 2025-Q2 to $42.9 million in 2026-Q2, reflecting a modest downward trend. The trajectory shows reaffirmation of guidance despite recent slight revenue declines, indicating management is maintaining its growth target.
“The Company is reaffirming its full year 2026 revenue at the lower end of its guidance range of approximately $151 to $157 million.”
“The Company is affirming its full year 2026 revenue and adjusted EBITDA guidance as follows: Revenue of approximately $151 to $157 million.”
“The Company projects full year 2026 revenue and adjusted EBITDA guidance as follows: Revenue of approximately $151 to $157 million.”
Over the next 1 to 3 years, AIRS's prospects will depend on management's execution and external market conditions. Not investment advice.